Opportunity Information: Apply for RFA AI 27 004
The Atopic Dermatitis Research Network (ADRN) (U19 Clinical Trial Optional) funding opportunity (RFA-AI-27-004) is a National Institutes of Health (NIH) cooperative agreement aimed at building and supporting a small network of research Centers focused on atopic dermatitis. The program is designed to bring together clinical and translational research in an integrated way, with the practical goal of improving how atopic dermatitis is understood and managed. A central scientific emphasis is placed on chronic skin inflammation and on the skin's defense mechanisms, meaning applicants are expected to address not only disease symptoms but also the underlying immunologic, barrier, and protective functions of the skin that contribute to disease onset, persistence, flares, and treatment response.
This opportunity uses the U19 mechanism, which typically supports multi-project, team-based Centers with coordinated research activities and close involvement from NIH staff under a cooperative agreement structure. The "clinical trial optional" designation indicates that applications may include clinical trials if they are scientifically justified, but a clinical trial is not required. In practical terms, this allows applicants to propose a spectrum of work ranging from human-focused mechanistic studies and biomarker research to interventional studies, as long as the overall Center approach tightly connects clinical observations with translational insights that can move the field forward.
Eligibility is broad across U.S.-based organization types and includes state, county, city/township, and special district governments; public and state-controlled institutions of higher education; private institutions of higher education; independent school districts; federally recognized Native American tribal governments and other tribal organizations; public housing authorities/Indian housing authorities; nonprofits both with and without 501(c)(3) status (excluding higher education where specified); for-profit organizations other than small businesses; and small businesses. However, the program explicitly excludes foreign participation in key ways: non-U.S. (foreign) organizations may not apply, non-U.S. components of U.S. organizations are not eligible, and foreign components as defined by the NIH Grants Policy Statement are not allowed. Applicants therefore need to structure their teams, sites, and project components so that all proposed work fits within these domestic eligibility boundaries.
Administratively, the opportunity sits in the health funding activity category and is associated with CFDA number 93.855. NIH anticipates making about four awards under this announcement, signaling a competitive process with a limited number of funded Centers. The original application due date is September 24, 2026, and the opportunity was created on June 29, 2026. An award ceiling is not specified in the provided summary, so applicants typically would need to consult the full NOFO for budget parameters, allowable costs, expectations for Center structure, required cores or shared resources (if applicable), and any network-wide coordination expectations.
Overall, this NOFO is best read as an invitation to propose a coordinated Center that connects patient-facing and clinic-based research with laboratory and translational efforts, all aimed at clarifying key drivers of atopic dermatitis and improving prevention, diagnosis, stratification, and management. The emphasis on chronic inflammation and skin defense suggests that strong applications will likely address immune pathways, barrier integrity, host-microbe interactions, and other protective functions of skin biology, while demonstrating a clear plan for how integrated projects will collectively produce actionable knowledge rather than isolated findings.Apply for RFA AI 27 004
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Atopic Dermatitis Research Network (ADRN) (U19 Clinical Trial Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.855.
- This funding opportunity was created on 2026-06-29.
- Applicants must submit their applications by 2026-09-24. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The number of recipients for this funding is limited to 4 candidate(s).
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
FAQs: Atopic Dermatitis Research Network (ADRN) (U19 Clinical Trial Optional) - RFA-AI-27-004
1) What is this funding opportunity?
This opportunity is the Atopic Dermatitis Research Network (ADRN) (U19 Clinical Trial Optional) funding opportunity, RFA-AI-27-004. It is a National Institutes of Health (NIH) cooperative agreement intended to build and support a small network of research Centers focused on atopic dermatitis.
2) What is the overall goal of the ADRN program?
The program is designed to bring together clinical and translational research in an integrated way, with the practical goal of improving how atopic dermatitis is understood and managed. The intent is for Centers to connect clinical observations with translational insights that can move the field forward.
3) What scientific areas are emphasized in this announcement?
A central emphasis is placed on chronic skin inflammation and the skin's defense mechanisms. This means applications are expected to address not only symptoms, but also underlying immunologic, barrier, and protective functions of the skin that contribute to disease onset, persistence, flares, and treatment response.
4) What does the U19 mechanism mean for applicants?
The U19 mechanism typically supports multi-project, team-based Centers with coordinated research activities. Because this is a cooperative agreement, NIH staff are expected to have close involvement consistent with the cooperative agreement structure.
5) Are clinical trials required?
No. The announcement is "clinical trial optional," meaning applications may include clinical trials if scientifically justified, but a clinical trial is not required.
6) If clinical trials are optional, what kinds of projects might fit?
Based on the description provided, proposed work may range from human-focused mechanistic studies and biomarker research to interventional studies, as long as the overall Center approach tightly connects clinical and translational components.
7) What is meant by an "integrated" clinical and translational Center approach?
The announcement frames this as a coordinated Center model where clinical observations and patient-facing research connect directly to laboratory and translational efforts. The goal is for the combined projects to produce actionable knowledge rather than isolated findings.
8) What types of organizations are eligible to apply?
Eligibility is broad across U.S.-based organizations and includes: state, county, city/township, and special district governments; public and state-controlled institutions of higher education; private institutions of higher education; independent school districts; federally recognized Native American tribal governments and other tribal organizations; public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status (excluding higher education where specified); for-profit organizations other than small businesses; and small businesses.
9) Are foreign organizations or foreign components allowed?
No. The program explicitly excludes foreign participation in key ways: non-U.S. (foreign) organizations may not apply, non-U.S. components of U.S. organizations are not eligible, and foreign components (as defined by the NIH Grants Policy Statement) are not allowed.
10) What does the foreign participation restriction mean in practice?
Applicants need to structure their teams, sites, and project components so that all proposed work fits within domestic eligibility boundaries, without foreign applicant organizations, non-U.S. components of U.S. organizations, or foreign components.
11) How many awards does NIH expect to make?
NIH anticipates making about four awards under this announcement, indicating a limited number of funded Centers.
12) When is the application due?
The original application due date listed is September 24, 2026.
13) When was this opportunity created?
The opportunity was created on June 29, 2026.
14) What is the funding activity category and CFDA number?
The opportunity sits in the health funding activity category and is associated with CFDA number 93.855.
15) Is there an award ceiling listed in the summary provided?
No. An award ceiling is not specified in the provided summary.
16) Where should applicants look for budget parameters and detailed requirements?
Because an award ceiling is not provided in the summary, applicants would typically need to consult the full NOFO for budget parameters, allowable costs, expectations for Center structure, any required cores or shared resources (if applicable), and any network-wide coordination expectations.
17) What kinds of scientific themes might a strong application emphasize?
The description suggests strong applications will likely address immune pathways, barrier integrity, host-microbe interactions, and other protective functions of skin biology, while demonstrating how integrated projects collectively clarify key drivers of atopic dermatitis and improve prevention, diagnosis, stratification, and management.
18) What is the practical outcome this network is aiming for?
The practical aim is to improve how atopic dermatitis is understood and managed, by generating integrated clinical and translational findings that clarify disease drivers and inform prevention, diagnosis, patient stratification, and management approaches.
Browse more opportunities from the same category: Health
Next opportunity: Fair Housing Initiatives Program - Education and Outreach Initiative
Previous opportunity: NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA AI 27 004
Applicants also applied for:
Applicants who have applied for this opportunity (RFA AI 27 004) also looked into and applied for these:
| Funding Opportunity |
|---|
| Metastasis Research Network (U54 Clinical Trial Not Allowed) Apply for RFA CA 27 012 Funding Number: RFA CA 27 012 Agency: National Institutes of Health Category: Health Funding Amount: $1,300,000 |
| Seed Instrumentation Support (SIS) Program (S10 Clinical Trial Not Allowed) Apply for PAR 27 021 Funding Number: PAR 27 021 Agency: National Institutes of Health Category: Health Funding Amount: $400,000 |
| Reducing the burden of parasitic infections in the United States through evidence-based prevention and control activities. Apply for CDC RFA CK 26 0221 Funding Number: CDC RFA CK 26 0221 Agency: Centers for Disease Control - NCEZID Category: Health Funding Amount: $1,250,000 |
| Increasing awareness and knowledge of Alpha-gal Syndrome in the United States Apply for CDC RFA CK 26 0193 Funding Number: CDC RFA CK 26 0193 Agency: Centers for Disease Control - NCEZID Category: Health Funding Amount: $1,000,000 |
| National Child Traumatic Stress Initiative - Treatment and Service Adaptation (TSA) Centers Apply for SM 26 003 Funding Number: SM 26 003 Agency: Substance Abuse and Mental Health Services Adminis Category: Health Funding Amount: $600,000 |
| National Center for Child Traumatic Stress - Category 1 Apply for SM 26 002 Funding Number: SM 26 002 Agency: Substance Abuse and Mental Health Services Adminis Category: Health Funding Amount: $8,000,000 |
| GLS Campus Suicide Prevention Grant Program Apply for SM 26 009 Funding Number: SM 26 009 Agency: Substance Abuse and Mental Health Services Adminis Category: Health Funding Amount: $125,000 |
| Project AWARE (Advancing Wellness and Resiliency in Education) Apply for SM 26 005 Funding Number: SM 26 005 Agency: Substance Abuse and Mental Health Services Adminis Category: Health Funding Amount: $1,500,000 |
| National Child Traumatic Stress Initiative - Community Treatment and Service Centers (CTS) Apply for SM 26 004 Funding Number: SM 26 004 Agency: Substance Abuse and Mental Health Services Adminis Category: Health Funding Amount: $600,000 |
| Adult Suicide Prevention Apply for SM 26 007 Funding Number: SM 26 007 Agency: Substance Abuse and Mental Health Services Adminis Category: Health Funding Amount: $400,000 |
| Providers Clinical Support System - Universities Apply for TI 26 001 Funding Number: TI 26 001 Agency: Substance Abuse and Mental Health Services Adminis Category: Health Funding Amount: $300,000 |
| Cooperative Agreements for Certified Community Behavioral Health Clinic (CCBHC) Planning Grants Apply for SM 26 016 Funding Number: SM 26 016 Agency: Substance Abuse and Mental Health Services Adminis Category: Health Funding Amount: $1,000,000 |
| Certified Community Behavioral Health Clinics (CCBHCs) Planning, Development, and Implementation Grant Apply for SM 26 014 Funding Number: SM 26 014 Agency: Substance Abuse and Mental Health Services Adminis Category: Health Funding Amount: $1,000,000 |
| Consumer and Consumer Support Technical Assistance Center Apply for SM 26 017 Funding Number: SM 26 017 Agency: Substance Abuse and Mental Health Services Adminis Category: Health Funding Amount: $1,782,291 |
| Certified Community Behavioral Health Clinic (CCBHC) Improvement and Advancement Grant Apply for SM 26 015 Funding Number: SM 26 015 Agency: Substance Abuse and Mental Health Services Adminis Category: Health Funding Amount: $1,000,000 |
| NIH Director’s Early Independence Award (DP5 Clinical Trial Optional) Apply for RFA RM 27 004 Funding Number: RFA RM 27 004 Agency: National Institutes of Health Category: Health Funding Amount: $350,000 |
| Rural Health Network Advancement Program Apply for HRSA 26 082 Funding Number: HRSA 26 082 Agency: Health Resources and Services Administration Category: Health Funding Amount: $500,000 |
| NIH Director’s New Innovator Award (DP2 Clinical Trial Optional) Apply for RFA RM 27 002 Funding Number: RFA RM 27 002 Agency: National Institutes of Health Category: Health Funding Amount: $475,000 |
| NIH Director’s Pioneer Award (DP1 Clinical Trial Optional) Apply for RFA RM 27 001 Funding Number: RFA RM 27 001 Agency: National Institutes of Health Category: Health Funding Amount: $700,000 |
| Sickle Cell Disease Regional Care Excellence (SoRCE) Program Apply for HRSA 26 052 Funding Number: HRSA 26 052 Agency: Health Resources and Services Administration Category: Health Funding Amount: $950,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA AI 27 004", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.